治験一覧
8,963 件中 5001〜5020 件を表示
日本人2型糖尿病患者を対象とした、エンパグリフロジンとリナグリプチン併用療法に関する研究
This trial will compare the use of fixed dose combination of empagliflozin and linagliptin to linagliptin alone in patient with type 2 diabetes mellitus
高血圧症の6歳以上16歳未満の小児患者を対象としたTAK-536（アジルサルタン）の第3相薬物動態試験
The purpose of this study is to evaluate the pharmacokinetics and safety of a single dose of TAK-536 (azilsartan) in pediatric patients aged 6 to less than 16 years with hypertension.
RAINBOW試験：未熟児網膜症を伴う早産児の治療におけるラニビズマブとレーザー療法との比較
The purpose of this study was to determine if intravitreal ranibizumab is superior to laser ablation therapy in the treatment of retinopathy of prematurity (ROP).
血液透析または血液濾過を受けている慢性腎不全患者における経口投与トルバプタン（OPC-41061）の有効性および安全性を調査する臨床試験
This is a study to investigate the efficacy and safety of OPC-41061 by 24-week oral administration of OPC-41061 at 15-mg or 30-mg or placebo in patients with chronic renal failure who are undergoing hemodialysis or hemodiafiltration and who have daily urine volume of at least 500 mL/day.
アルコール依存症患者におけるナルメフェンのアルコール摂取量減少効果を調査するための、多施設共同、無作為化、二重盲検、プラセボ対照、3群並行比較試験（第3相試験）
The efficacy, safety, and dose-response of nalmefene hydrochloride at 10 mg and 20 mg in patients with alcohol dependence will be evaluated in a multicenter, randomized, double-blind, placebo-controlled, 3-parallel-group comparative trial. The superiority of nalmefene hydrochloride at 20 mg to placebo will be verified in terms of reduction of alcohol consumption.
TAK-114単回投与および複数回投与第1相試験
The purpose of this study is to evaluate the safety and tolerability of TAK-114 following single and multiple ascending oral doses in healthy Japanese male participants.
急性冠症候群患者を対象に、クロピドグレルまたはチカグレロル療法に加えてリバーロキサバンとアセチルサリチル酸を併用した場合の安全性を比較する研究
The purpose of this study is to estimate the risk of bleeding with rivaroxaban, compared with acetylsalicylic acid (ASA), in addition to a single antiplatelet/ platelet adenosine diphosphate P2Y12 receptor antagonist (P2Y12 inhibitor agent: clopidogrel or ticagrelor), in participants with a recent acute coronary syndrome (ACS: including ST segment elevation myocardial infarction \[STEMI\] and non-ST-segment elevation acute coronary syndrome \[NSTE-ACS\]).
大うつ病性障害患者を対象としたLu AA21004の第3相臨床試験
The purpose of this study is to evaluate the efficacy of two fixed doses of vortioxetine (Lu AA21004; 10 or 20 mg/day) after 8 weeks of treatment in patients with major depressive disorder (MDD) in Japan.
PCA062はpCAD陽性腫瘍に有効である。
A first-in-human sttudy using PCA062 in patients with p-CAD positive solid tumors.
併存する心血管疾患を有する患者に対するベタニス錠の特定薬剤使用結果調査
This purpose of this study is to investigate the effects of mirabegron on the cardiovascular system in patients with overactive bladder with current or a history of cardiovascular disease.
中等度から重度の関節リウマチ（RA）患者を対象とした、ナミルマブとメトトレキサート併用療法の用量探索試験
The purpose of this study is to establish proof of concept and identify the optimal efficacious dose for namilumab in RA in patients with an inadequate response to methotrexate (MTX-IR) and in patients with an inadequate response to one tumor necrosis factor (TNF)-inhibitor (TNF-IR).
糖尿病黄斑浮腫眼におけるルセンティス（ラニビズマブ）硝子体内投与後の酸素消費量の変化
Recent reports suggest that anti-VEGF agents (ranibizumab) may suppress the progression of retinal nonperfusion area. This protective effect would cause the increase of the oxygen consumption in the diabetic retina. We expect that the current study using the retinal oximetry would show the protective effects of ranibizumab on the hypoxia in the diabetic retina. This study is designed to analyze the effects of ranibizumab (Lucentis) to the retinal oxygen saturation or consumption in eyes with diabetic macular edema.
尿路上皮癌におけるMEDI4736（デュルバルマブ）とトレメリムマブの併用または非併用療法と標準化学療法を比較する試験
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Stage IV Urothelial Cancer
症状のある末梢動脈疾患患者が下肢末梢血管再建術を受ける際の、リバーロキサバンによる主要血栓性血管イベントリスク低減効果と安全性
The purpose of study was to test whether rivaroxaban added to standard of care treatment, when compared to placebo, had the potential to reduce the incidence of the clinical events related to the clots and complications of the heart and brain (CV death, MI, or stroke) or the legs (acute limb ischemia or major amputation) in patients who had undergone recent procedure(s) to improve the blood flow of their legs.
日本における滲出型加齢黄斑変性症（wAMD）患者の介護者の負担
This study aims at investigation of the caregiver burden of Wet Age-related Macular Degeneration (wAMD) patients and at the assessment of how much of caregiver burden could be reduced in transitioning from Pro Re Nata to proactive therapy especially in real-life rural settings where public transportations are not readily available.
ビスホスホネート治療に反応しない骨粗鬆症患者におけるエルデカルシトールの有効性
In the patients with osteoporosis, bisphosphonates (BPs) are a golden standard treatment. However, the bone turnover markers or the bone mineral density (BMD) are not improved in some osteoporotic patients even though they have taken BPs and alfacalcidol more than several years. In those case, the investigators better off prescribing BPs and Eldecalcitol, instead of BPs and Alfacalcitol.
放射性ヨウ素（RAI）治療抵抗性の分化型甲状腺癌におけるマルチキナーゼ阻害剤の使用を評価するための観察研究
The purpose of the study was to assess the use of Multikinase Inhibitors (MKIs) in the treatment of patients with a progressive differentiated thyroid carcinoma (DTC) refractory to radioactive iodine (RAI) who do not have any symptoms.
19G Flexを用いたEUSガイド下経十二指腸生検
This study evaluates the feasibility, safety and accuracy of a 19 gauge (19G) needle in nitinol in the performance of endoscopic ultrasound (EUS) guided transduodenal biopsy for the acquisition of samples for histologic analysis. Patients with lesions that can be approached only from the duodenum will be prospectively enrolled.
TBI-1301の医師主導型第1相臨床試験
Following pre-treatment with cyclophosphamide and/or fludarabine, NY-ESO-1-specific TCR gene transduced T lymphocytes are transferred to the patients with NY-ESO-1-expressing solid tumors.
再発・難治性多発性骨髄腫の成人患者における、カルフィルゾミブとデキサメタゾンの併用療法における週1回投与と週2回投与の比較
The purpose of the study is to compare the progression-free survival (PFS) of once-weekly carfilzomib dosing in combination with dexamethasone to twice-weekly carfilzomib dosing in combination with dexamethasone in adults with relapsed and refractory multiple myeloma, previously treated with bortezomib and an immunomodulatory agent (IMiD).